Literature DB >> 28654300

A New Optimized Percutaneous Access System for CIPII.

Rosa Garcia-Verdugo1, Michael Erbach1, Oliver Schnell1,2.   

Abstract

In recent years, continuous intraperitoneal insulin infusion (CIPII) has become a favored treatment alternative for patients with subcutaneous insulin resistance, mainly due to its ability of mimicking physiological conditions of insulin absorption. CIPII has been shown to improve glycemic control as well as to reduce hypoglycemic events and to lead to increased patient satisfaction and quality of life (QoL). Among CIPII delivery systems, Diaport stands out due to its low side effects, its demonstrated clinical efficacy and the potential for integration into closed-loop systems.

Entities:  

Keywords:  CIPII; hypoglycemia; subcutaneous insulin resistance; type 1 diabetes

Mesh：

Substances：

Year:  2017        PMID： 28654300      PMCID： PMC5588834          DOI： 10.1177/1932296817694913

Source DB:  PubMed          Journal:  J Diabetes Sci Technol        ISSN： 1932-2968


  70 in total

1.  Splanchnic and systemic absorption of intraperitoneal insulin using a new double-tracer method.

Authors:  J Radziuk; S Pye; D E Seigler; J S Skyler; R Offord; G Davies
Journal:  Am J Physiol       Date:  1994-05

2.  Increased responses of glucagon and glucose production to hypoglycemia with intraperitoneal versus subcutaneous insulin treatment.

Authors:  C K Wan; A Giacca; M Matsuhisa; B El-Bahrani; L Lam; C Rodgers; Z Q Shi
Journal:  Metabolism       Date:  2000-08       Impact factor: 8.694

Review 3.  Intraperitoneal insulin infusion: treatment option for type 1 diabetes resulting in beneficial endocrine effects beyond glycaemia.

Authors:  P R van Dijk; S J J Logtenberg; R O B Gans; H J G Bilo; N Kleefstra
Journal:  Clin Endocrinol (Oxf)       Date:  2014-07-28       Impact factor: 3.478

4.  In search of the subcutaneous-insulin-resistance syndrome.

Authors:  D S Schade; W C Duckworth
Journal:  N Engl J Med       Date:  1986-07-17       Impact factor: 91.245

5.  Improved glycemic control with intraperitoneal versus subcutaneous insulin in type 1 diabetes: a randomized controlled trial.

Authors:  Susan J Logtenberg; Nanne Kleefstra; Sebastiaan T Houweling; Klaas H Groenier; Reinold O Gans; Evert van Ballegooie; Henk J Bilo
Journal:  Diabetes Care       Date:  2009-05-08       Impact factor: 17.152

6.  Insulin delivery route for the artificial pancreas: subcutaneous, intraperitoneal, or intravenous? Pros and cons.

Authors:  Eric Renard
Journal:  J Diabetes Sci Technol       Date:  2008-07

7.  Successful treatment with insulin analog lispro in IDDM with delayed absorption of subcutaneously applied human regular insulin and complicated intraperitoneal insulin infusion. A case report.

Authors:  M Meier; J Brand; E Standl; O Schnell
Journal:  Diabetes Care       Date:  1998-07       Impact factor: 19.112

8.  Intraperitoneal insulin therapy corrects abnormalities in cholesteryl ester transfer and lipoprotein lipase activities in insulin-dependent diabetes mellitus.

Authors:  J D Bagdade; F L Dunn; R H Eckel; M C Ritter
Journal:  Arterioscler Thromb       Date:  1994-12

9.  Intraperitoneal versus subcutaneous insulin therapy in the treatment of type 1 diabetes mellitus.

Authors:  P R van Dijk; S J J Logtenberg; S H Hendriks; K H Groenier; J Feenstra; F Pouwer; R O B Gans; N Kleefstra; H J G Bilo
Journal:  Neth J Med       Date:  2015-11       Impact factor: 1.422

Review 10.  Artificial pancreas: past, present, future.

Authors:  Claudio Cobelli; Eric Renard; Boris Kovatchev
Journal:  Diabetes       Date:  2011-11       Impact factor: 9.461
View more
  4 in total

1.  Analysis of "A New Optimized Percutaneous Access System for CIPII".

Authors:  Eric Renard
Journal:  J Diabetes Sci Technol       Date:  2017-04-13

2.  New Design of a Percutaneous Port System for Continuous Intraperitoneal Insulin Infusion.

Authors:  Cosima Rieger; Klaus Kurz; Wiebke Mueller-Hoffmann; Bernhard Gehr; Andreas Liebl
Journal:  J Diabetes Sci Technol       Date:  2019-06-13

3.  Intraperitoneal insulin delivery provides superior glycaemic regulation to subcutaneous insulin delivery in model predictive control-based fully-automated artificial pancreas in patients with type 1 diabetes: a pilot study.

Authors:  Eyal Dassau; Eric Renard; Jérôme Place; Anne Farret; Marie-José Pelletier; Justin Lee; Lauren M Huyett; Ankush Chakrabarty; Francis J Doyle; Howard C Zisser
Journal:  Diabetes Obes Metab       Date:  2017-07-06       Impact factor: 6.577

Review 4.  Evolution of Insulin Delivery Devices: From Syringes, Pens, and Pumps to DIY Artificial Pancreas.

Authors:  Jothydev Kesavadev; Banshi Saboo; Meera B Krishna; Gopika Krishnan
Journal:  Diabetes Ther       Date:  2020-05-14       Impact factor: 2.945
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.